MedPath

Jiangsu Province Hospital (The First Affiliated Hospital With Nanjing Medical University)

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

Phase 2
Not yet recruiting
Conditions
EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Brentuximab Vedotin
Interventions
Drug: BV+R-CHP
First Posted Date
2025-04-13
Last Posted Date
2025-04-13
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
25
Registration Number
NCT06925555
Locations
🇨🇳

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer

Active, not recruiting
Conditions
Advanced Breast Cancer
Interventions
Drug: Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety
First Posted Date
2025-04-13
Last Posted Date
2025-04-13
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
500
Registration Number
NCT06926088
Locations
🇨🇳

Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China

Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors

Not Applicable
Recruiting
Conditions
RCC, Renal Cell Cancer
Partial Nephrectomy
First Posted Date
2025-04-03
Last Posted Date
2025-04-03
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
60
Registration Number
NCT06908902
Locations
🇨🇳

The first affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China

A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)

Phase 3
Not yet recruiting
Conditions
Bronchial Asthma
Interventions
Drug: Budesonide Formoterol
Drug: Placebo
Drug: Immune Modulators (Staphylococcus and Neisseria Tablets)
First Posted Date
2025-03-26
Last Posted Date
2025-06-05
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
198
Registration Number
NCT06895460
Locations
🇨🇳

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, Nanjing, Jiangsu, China

Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy

Phase 2
Recruiting
Conditions
Gastric Cancers
Interventions
Drug: Pre-operative chemotherapy
Procedure: Robotic radical gastrectomy after neoadjuvant therapy
First Posted Date
2025-03-26
Last Posted Date
2025-07-01
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
40
Registration Number
NCT06895447
Locations
🇨🇳

First Affiliated Hospital of Nanjing Medical Unviersity, Nanjing, Jiangsu, China

🇨🇳

First Affiliated Hospital of Nanjing Medical Unviersity, Nanjing, Jiangsu, China

Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis

Phase 4
Not yet recruiting
Conditions
Pancreatic Cancer
Maintenance Therapy
Postoperative Adjuvant Therapy
Interventions
First Posted Date
2025-03-25
Last Posted Date
2025-04-03
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
464
Registration Number
NCT06779318
Locations
🇨🇳

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

Phase 2
Recruiting
Conditions
Chidamide
R-CHOP Chemotherapy
DLBCL - Diffuse Large B Cell Lymphoma
Double-expressor Lymphoma (DEL)
Interventions
Drug: Chidamide plus R-CHOP
First Posted Date
2025-03-24
Last Posted Date
2025-03-24
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
148
Registration Number
NCT06891157
Locations
🇨🇳

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Early Phase 1
Active, not recruiting
Conditions
Colorectal Cancer
Interventions
Drug: Anlotinib hydrochloride,Penpulimab
First Posted Date
2025-03-03
Last Posted Date
2025-03-03
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
48
Registration Number
NCT06853769
Locations
🇨🇳

Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China

Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

Phase 2
Not yet recruiting
Conditions
Thymic Carcinoma
Thymoma
First Posted Date
2025-02-21
Last Posted Date
2025-02-21
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
20
Registration Number
NCT06838910
Locations
🇨🇳

The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath